ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Pathological Characteristics and Prognosis of Breast Cancer During Pregnancy and Postpartum: A Multicenter Retrospective Study.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPostpartum diagnosis of breast cancer confers increased risk of metastasis and death, possibly because of protumorigenic pathways that occur after weaning. We sought to evaluate the impact of postpartum diagnosis on survival in patients with inflammatory breast cancer (IBC).
methodsWe performed a retrospective analysis of patients with nonmetastatic IBC enrolled in a prospective registry (2007-2023). Kruskal-Wallis, χ2, and Fisher exact tests were used to compare between postpartum groups. The Kaplan-Meier method and log-rank tests were used for survival estimates.
resultsAmong 320 patients with IBC, 25 (7.8%) were nulliparous, 31 (9.7%) were 0 to 5 years postpartum, 26 (8.1%) were 6 to 10 years postpartum, 56 (17.5%) were 11 to 20 years postpartum, and 182 (56.9%) were >20 years postpartum. Groups were similar with respect to race/ethnicity, body mass index, grade, receptor subtype, stage, trimodality therapy receipt, and pathologic complete response rate. At a median follow-up of 77 months (95% confidence interval, 69.3-86.5), there were no significant differences in overall survival, progression-free survival, and locoregional and distant recurrence-free survival by postpartum status. On multivariable analysis, parity status and years postpartum were not significantly associated with survival outcomes after controlling for age, stage, and receptor subtype.
conclusionsIn this cohort of patients with IBC with a high proportion of childbearing, postpartum diagnosis did not significantly affect survival outcomes. The aggressive biology of IBC may override any additional risks imposed by a postpartum diagnosis. IMPACT: Unlike in noninflammatory invasive breast cancer, postpartum diagnosis did not negatively affect prognosis in IBC. These findings highlight the continuing need to identify unique drivers of aggressive biology in IBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.